AKTX
Akari TherapeuticsAKTX
AKTX
About: Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Employees: 12
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
40% more funds holding
Funds holding: 10 [Q3] → 14 (+4) [Q4]
0% less ownership
Funds ownership: 0% [Q3] → 0% (-0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
27% less capital invested
Capital invested by funds: $536K [Q3] → $394K (-$142K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AKTX.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B
Neutral
GlobeNewsWire
1 month ago
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds.
Neutral
GlobeNewsWire
1 month ago
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Akari in 2025.
Neutral
GlobeNewsWire
2 months ago
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Akari's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base.
Neutral
GlobeNewsWire
3 months ago
Akari Therapeutics Announces Key Leadership Appointments
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R.
Neutral
GlobeNewsWire
3 months ago
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe.
Neutral
GlobeNewsWire
4 months ago
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -
Neutral
GlobeNewsWire
4 months ago
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support.
Neutral
Accesswire
5 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Akari Therapeutics, PLC (NASDAQ:AKTX) , relating to its proposed merger with Peak Bio, Inc. Under the terms of the agreement, Akari shareholders are expected to own approximately 52% of the combined company.
Neutral
GlobeNewsWire
7 months ago
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Charts implemented using Lightweight Charts™